Government-Owned Inventions; Availability for Licensing, 49389-49390 [2017-23177]
Download as PDF
<![CDATA[
sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 82, No. 205 / Wednesday, October 25, 2017 / Notices
Site Studies for System-Level
Implementation of Substance Use Prevention
and Treatment Services (R01; R34).
Date: November 7, 2017.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, DHHS, 6001
Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892–9550, 301–827–5819,
gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Limited
Competition—Cohort Studies of HIV/AIDS
and Substance Abuse (U01).
Date: November 7, 2017.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Advancing Exceptional Research on HIV/
AIDS and Substance Abuse (R01).
Date: November 10, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, National Institutes
of Health, DHHS, 6001 Executive Boulevard,
Room 4238, MSC 9550, Bethesda, MD 20892,
301–827–5820, hiromi.ono@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Wearable to Track Recovery and Relapse
Factors for People w/Addiction (R43, R44).
Date: November 21, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
VerDate Sep<11>2014
22:06 Oct 24, 2017
Jkt 244001
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; NIDA
Research Education Program for Clinical
Researchers and Clinicians (R25).
Date: December 4, 2017.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, DHHS, 6001
Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892–9550, 301–827–5819,
gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Nasal
Delivery of CNS Therapeutics (R41, R42, R43,
R44).
Date: December 5, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Julia Berzhanskaya, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4234, MSC 9550, Bethesda,
MD 20892, 301–827–5840,
julia.berzhanskaya@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Conference Grant Review (R13).
Date: December 6, 2017.
Time: 1:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Shang-Yi Anne Tsai,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4228, MSC 9550, Bethesda,
MD 20892, 301–827–5842, shangyi.tsai@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: October 19, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–23128 Filed 10–24–17; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00079
Fmt 4703
Sfmt 4703
49389
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT: Dr.
Amy Petrik, 240–627–3721;
amy.petrik@nih.gov. Licensing
information and copies of the U.S.
patent application listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
SUMMARY:
Neutralizing Antibodies to Influenza
HA and Their Use and Identification
Description of Technology: The
effectiveness of current influenza
vaccines varies by strain and season, in
part because influenza viruses
continuously evolve to evade human
immune responses. While the majority
of seasonal influenza infections cause
relatively mild symptoms, each year
influenza virus infections result in over
500,000 hospitalizations in the United
States and Europe. Current standard of
care for individuals hospitalized with
uncomplicated influenza infection is
administration of neuraminidase
inhibitors. However, frequent use of
such antiviral drugs increases the risk
that the virus will develop drug
resistance, especially in high-risk
populations. Thus, alternative strategies
are required to protect or treat
vulnerable populations who have been
hospitalized with severe influenza.
Using a combination of recombinant
proteins and sophisticated flow
cytometry, scientists at NIAID isolated
families of antibodies capable of
E:\FR\FM\25OCN1.SGM
25OCN1
sradovich on DSK3GMQ082PROD with NOTICES
49390
Federal Register / Vol. 82, No. 205 / Wednesday, October 25, 2017 / Notices
neutralizing diverse group 1 and group
2 influenza A viruses. Specifically, the
families of antibodies identified
precisely target parts of the
hemagglutinin (HA) protein, present on
the surface of the influenza virus, that
are least variable from season to season
(Joyce, M.G., et al. Cell (2016) 166 (3):
609–623). Therefore, it is hypothesized
that passive administration of members
of these families of antibodies to
individuals would represent an
alternative to the current standard of
care for severe influenza virus infection.
Additionally, these families of
antibodies could be useful for
development of a product aimed at
conferring passive immunity in
vulnerable populations during the time
of an outbreak or emergence of a
pandemic strain of influenza.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
NIAID is continuing development of
these neutralizing antibodies to
influenza toward a clinical product for
treatment and/or prevention of
influenza virus infection. Consequently,
for some fields of use, NIAID will
evaluate a license applicant’s
capabilities and experience in
advancing similar technologies through
the regulatory process.
Potential Commercial Applications:
• Prevention of influenza A virus
infection
• Therapeutic intervention to treat
influenza infection
Competitive Advantages:
• Ability to potently neutralize both
group 1 and group 2 influenza A strains
Development Stage:
• Proof of concept in animal models
Inventors: Adrian McDermott (NIAID),
Peter Kwong (NIAID), John Mascola
(NIAID), M. Gordon Joyce (NIAID),
Robert Bailer (NIAID), Sarah Andrews
(NIAID), Paul Thomas (NIAID), Gwo-Yu
Chuang (NIAID), Adam Wheatley
(NIAID), Yi Zhang (NIAID), James
Whittle (NIAID).
Publications: Joyce, M.G., et al. Cell
(2016) 166 (3): 609–623
Intellectual Property: HHS Reference
No. E–061–2016—US Patent
Application No. 62/330,837 filed May 2,
2016; Patent Cooperation Treaty
Application No. PCT/US2017/030641
filed May 2, 2017.
Licensing Contact: Dr. Amy Petrik,
240–627–3721; amy.petrik@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
VerDate Sep<11>2014
22:06 Oct 24, 2017
Jkt 244001
interested in collaborative research to
further develop, evaluate or
commercialize influenza monoclonal
antibody technologies. For collaboration
opportunities, please contact Dr. Amy
Petrik, 240–627–3721; amy.petrik@
nih.gov.
Dated: October 19, 2017.
Suzanne Frisbie,
Deputy Director,Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–23177 Filed 10–24–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[Docket No. USCG–2017–0124]
Collection of Information Under
Review by Office of Management and
Budget; OMB Control Number: 1625–
0057
Coast Guard, DHS.
Thirty-day notice requesting
comments.
AGENCY:
ACTION:
In compliance with the
Paperwork Reduction Act of 1995 the
U.S. Coast Guard is forwarding an
Information Collection Request (ICR),
abstracted below, to the Office of
Management and Budget (OMB), Office
of Information and Regulatory Affairs
(OIRA), requesting approval for
reinstatement, without change, of the
following collection of information:
1625–0057, Small Passenger Vessels—
Title 46 Subchapters K and T. Our ICR
describes the information we seek to
collect from the public. Review and
comments by OIRA ensure we only
impose paperwork burdens
commensurate with our performance of
duties.
DATES: Comments must reach the Coast
Guard and OIRA on or before November
24, 2017.
ADDRESSES: You may submit comments
identified by Coast Guard docket
number [USCG–2017–0124] to the Coast
Guard using the Federal eRulemaking
Portal at https://www.regulations.gov.
Alternatively, you may submit
comments to OIRA using one of the
following means:
(1) Email: dhsdeskofficer@
omb.eop.gov.
(2) Mail: OIRA, 725 17th Street NW.,
Washington, DC 20503, attention Desk
Officer for the Coast Guard.
A copy of the ICR is available through
the docket on the Internet at https://
www.regulations.gov. Additionally,
SUMMARY:
PO 00000
Frm 00080
Fmt 4703
Sfmt 4703
copies are available from: Commandant
(CG–612), Attn: Paperwork Reduction
Act Manager, U.S. Coast Guard, 2703
Martin Luther King Jr. Ave. SE., Stop
7710, Washington, DC 20593–7710.
FOR FURTHER INFORMATION: Contact Mr.
Anthony Smith, Office of Information
Management, telephone 202–475–3532,
or fax 202–372–8405, for questions on
these documents.
SUPPLEMENTARY INFORMATION:
Public Participation and Request for
Comments
This Notice relies on the authority of
the Paperwork Reduction Act of 1995;
44 U.S.C. Chapter 35, as amended. An
ICR is an application to OIRA seeking
the approval, extension, or renewal of a
Coast Guard collection of information
(Collection). The ICR contains
information describing the Collection’s
purpose, the Collection’s likely burden
on the affected public, an explanation of
the necessity of the Collection, and
other important information describing
the Collection. There is one ICR for each
Collection.
The Coast Guard invites comments on
whether this ICR should be granted
based on the Collection being necessary
for the proper performance of
Departmental functions. In particular,
the Coast Guard would appreciate
comments addressing: (1) The practical
utility of the Collection; (2) the accuracy
of the estimated burden of the
Collection; (3) ways to enhance the
quality, utility, and clarity of
information subject to the Collection;
and (4) ways to minimize the burden of
the Collection on respondents,
including the use of automated
collection techniques or other forms of
information technology. These
comments will help OIRA determine
whether to approve the ICR referred to
in this Notice.
We encourage you to respond to this
request by submitting comments and
related materials. Comments to Coast
Guard or OIRA must contain the OMB
Control Number of the ICR. They must
also contain the docket number of this
request, [USCG–2017–0124], and must
be received by November 24, 2017.
Submitting Comments
We encourage you to submit
comments through the Federal
eRulemaking Portal at https://
www.regulations.gov. If your material
cannot be submitted using https://
www.regulations.gov, contact the person
in the FOR FURTHER INFORMATION
CONTACT section of this document for
alternate instructions. Documents
mentioned in this notice, and all public
E:\FR\FM\25OCN1.SGM
25OCN1
]]>Agencies
[Federal Register Volume 82, Number 205 (Wednesday, October 25, 2017)]
[Notices]
[Pages 49389-49390]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-23177]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Dr. Amy Petrik, 240-627-3721;
[email protected]. Licensing information and copies of the U.S. patent
application listed below may be obtained by communicating with the
indicated licensing contact at the Technology Transfer and Intellectual
Property Office, National Institute of Allergy and Infectious Diseases,
5601 Fishers Lane, Rockville, MD, 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Neutralizing Antibodies to Influenza HA and Their Use and
Identification
Description of Technology: The effectiveness of current influenza
vaccines varies by strain and season, in part because influenza viruses
continuously evolve to evade human immune responses. While the majority
of seasonal influenza infections cause relatively mild symptoms, each
year influenza virus infections result in over 500,000 hospitalizations
in the United States and Europe. Current standard of care for
individuals hospitalized with uncomplicated influenza infection is
administration of neuraminidase inhibitors. However, frequent use of
such antiviral drugs increases the risk that the virus will develop
drug resistance, especially in high-risk populations. Thus, alternative
strategies are required to protect or treat vulnerable populations who
have been hospitalized with severe influenza.
Using a combination of recombinant proteins and sophisticated flow
cytometry, scientists at NIAID isolated families of antibodies capable
of
[[Page 49390]]
neutralizing diverse group 1 and group 2 influenza A viruses.
Specifically, the families of antibodies identified precisely target
parts of the hemagglutinin (HA) protein, present on the surface of the
influenza virus, that are least variable from season to season (Joyce,
M.G., et al. Cell (2016) 166 (3): 609-623). Therefore, it is
hypothesized that passive administration of members of these families
of antibodies to individuals would represent an alternative to the
current standard of care for severe influenza virus infection.
Additionally, these families of antibodies could be useful for
development of a product aimed at conferring passive immunity in
vulnerable populations during the time of an outbreak or emergence of a
pandemic strain of influenza.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
NIAID is continuing development of these neutralizing antibodies to
influenza toward a clinical product for treatment and/or prevention of
influenza virus infection. Consequently, for some fields of use, NIAID
will evaluate a license applicant's capabilities and experience in
advancing similar technologies through the regulatory process.
Potential Commercial Applications:
Prevention of influenza A virus infection
Therapeutic intervention to treat influenza infection
Competitive Advantages:
Ability to potently neutralize both group 1 and group 2
influenza A strains
Development Stage:
Proof of concept in animal models
Inventors: Adrian McDermott (NIAID), Peter Kwong (NIAID), John
Mascola (NIAID), M. Gordon Joyce (NIAID), Robert Bailer (NIAID), Sarah
Andrews (NIAID), Paul Thomas (NIAID), Gwo-Yu Chuang (NIAID), Adam
Wheatley (NIAID), Yi Zhang (NIAID), James Whittle (NIAID).
Publications: Joyce, M.G., et al. Cell (2016) 166 (3): 609-623
Intellectual Property: HHS Reference No. E-061-2016--US Patent
Application No. 62/330,837 filed May 2, 2016; Patent Cooperation Treaty
Application No. PCT/US2017/030641 filed May 2, 2017.
Licensing Contact: Dr. Amy Petrik, 240-627-3721;
[email protected].
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize influenza monoclonal antibody
technologies. For collaboration opportunities, please contact Dr. Amy
Petrik, 240-627-3721; [email protected].
Dated: October 19, 2017.
Suzanne Frisbie,
Deputy Director,Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-23177 Filed 10-24-17; 8:45 am]
BILLING CODE 4140-01-P
